Bioksan is re -appearing on the list of the Financial Times of compani

Bioksan reappears for the second consecutive year in the FT 1000: The sixth annual list of higher European companies according to the Financial Times.

The classification, prepared with the statista research company, lists European companies that achieved the highest annual growth rate composed of income between 2017 and 2020. The minimum compound annual rate required to appear on the list was 36.5%, a level higher than 35.5% necessary for last year classification.

Only 306 of these 1000 companies repeat in this classification and Bioksan is one of them, appearing in 610th position. Within the sector of the Bioksan nutraceutical it holds the 12th position at European level, considered in turn, the company number 30 of the 49 of the 49 Spanish that enter the classification of the Financial Times this year.

Bioksan Company 610 of the 1000 European companies with the highest growth.

Bioksan 12th Company of the Nutraceutic Sector
At European level.
Bioksan put 30 of 49 Spanish companies.

In a historical moment marked by the collapse of the demand caused by the pandemic, the commercial friction of the Brexit and a long contraction of the world supply chain, the FT 1000 highlights the resilience of the European business framework, where technology and construction lead The top positions on the list, highlighting the surprise paper of companies such as Bioksan that break into other sectors such as Food Tech to return optimism to the economy, despite the new risks that suppose the shortage of labor, the increase in the inflation, the war of Ukraine and the rise in energy prices.

Bioksan, following this trail of development and expansion faces the first half of 2022 with a growth rate of 18.50%, according to internal data, while facing its first step in internationalization to begin its activity imminently in Portugal, and open its first headquarters in Italy before the end of the year. New developing products, new lines, expansion of its commercial network and its unstoppable scientific contribution will mark its agenda for what remains of 2022.